<DOC>
	<DOCNO>NCT02864927</DOCNO>
	<brief_summary>The purpose study perform re-examination Menactra® administer routine clinical setting accordance Ministry Food Drug Safety regulation . Primary objective : - To describe safety profile 1 dose Menactra® administer 9 month 55 year age standard health care practice .</brief_summary>
	<brief_title>Postmarketing Surveillance Study Use Menactra® Republic Korea</brief_title>
	<detailed_description>Subjects age 9 month 55 year give study vaccine routine health-care visit enrol study . They followed-up Day 42 follow vaccination . No study vaccine supply administer part study , subject monitor follow routine vaccine administration clinical setting .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed consent form sign subject ( subject 19 55 year age ) parent ( ) legal representative ( subject 9 month 18 year age ) Receipt one dose Menactra® ( day inclusion ) accord approve local product insert paper . Participation time study enrollment ( 4 week precede study vaccination ) plan participation present study period another clinical study investigate vaccine , drug , medical device , medical procedure Subjects already participate study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Meningococcal Vaccine</keyword>
</DOC>